Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report
Pediatric glioblastoma multiforme is an uncommon and highly mortal brain cancer. New therapeutic treatments are being intensively investigated by researchers in order to extend the survival of patients. The immune checkpoint inhibitor nivolumab in the treatment of pediatric glioblastoma multiforme i...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-11-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1010-660X/54/5/82 |
| _version_ | 1797727566222589952 |
|---|---|
| author | Ömer Kartal Erman Ataş |
| author_facet | Ömer Kartal Erman Ataş |
| author_sort | Ömer Kartal |
| collection | DOAJ |
| description | Pediatric glioblastoma multiforme is an uncommon and highly mortal brain cancer. New therapeutic treatments are being intensively investigated by researchers in order to extend the survival of patients. The immune checkpoint inhibitor nivolumab in the treatment of pediatric glioblastoma multiforme is currently under review; it is a human immunoglobulin G4 monoclonal antibody that works against the programmed cell death protein 1 receptor, designed to enhance an immunologic reaction against cancer cells. Herein, we describe the first report of a bilateral optic neuritis induced by nivolumab in a grade 4 glioblastoma multiforme patient. |
| first_indexed | 2024-03-12T11:01:31Z |
| format | Article |
| id | doaj.art-74c8d4c8793f4b27917e46b74d6d360f |
| institution | Directory Open Access Journal |
| issn | 1010-660X |
| language | English |
| last_indexed | 2024-03-12T11:01:31Z |
| publishDate | 2018-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-74c8d4c8793f4b27917e46b74d6d360f2023-09-02T05:30:56ZengMDPI AGMedicina1010-660X2018-11-015458210.3390/medicina54050082medicina54050082Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case ReportÖmer Kartal0Erman Ataş1Division of Pediatric Hematology and Oncology, Gülhane Training and Research Hospital, 06300 Ankara, TurkeyDivision of Pediatric Oncology, Gülhane Training and Research Hospital, 06300 Ankara, TurkeyPediatric glioblastoma multiforme is an uncommon and highly mortal brain cancer. New therapeutic treatments are being intensively investigated by researchers in order to extend the survival of patients. The immune checkpoint inhibitor nivolumab in the treatment of pediatric glioblastoma multiforme is currently under review; it is a human immunoglobulin G4 monoclonal antibody that works against the programmed cell death protein 1 receptor, designed to enhance an immunologic reaction against cancer cells. Herein, we describe the first report of a bilateral optic neuritis induced by nivolumab in a grade 4 glioblastoma multiforme patient.https://www.mdpi.com/1010-660X/54/5/82glioblastoma multiformenivolumaboptic neuritis |
| spellingShingle | Ömer Kartal Erman Ataş Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report Medicina glioblastoma multiforme nivolumab optic neuritis |
| title | Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report |
| title_full | Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report |
| title_fullStr | Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report |
| title_full_unstemmed | Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report |
| title_short | Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report |
| title_sort | bilateral optic neuritis secondary to nivolumab therapy a case report |
| topic | glioblastoma multiforme nivolumab optic neuritis |
| url | https://www.mdpi.com/1010-660X/54/5/82 |
| work_keys_str_mv | AT omerkartal bilateralopticneuritissecondarytonivolumabtherapyacasereport AT ermanatas bilateralopticneuritissecondarytonivolumabtherapyacasereport |